» Articles » PMID: 30333813

Characterization of Inducible Transcription and Translation-Competent HIV-1 Using the RNAscope ISH Technology at a Single-Cell Resolution

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2018 Oct 19
PMID 30333813
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Identifying the source and dynamics of persistent HIV-1 at single-cell resolution during cART is crucial for the design of strategies to eliminate the latent HIV-1 reservoir. An assay to measure latent HIV-1 that can distinguish inducible from defective proviruses with high precision is essential to evaluate the efficacy of HIV-1 cure efforts but is presently lacking. The primary aim of this study was therefore to identify transcription and translation competent latently infected cells through detection of biomolecules that are dependent on transcriptional activation of the provirus. We investigated the applicability of two commercially available assays; PrimeFlow RNA Assay (RNAflow) and RNAscope ISH (RNAscope) for evaluation of the efficacy of latency reversal agents (LRAs) to reactivate the HIV-1 latent reservoir. The J-Lat cell model (clones 6.3, 9.3, and 10.6) and four LRAs was used to evaluate the sensitivity, specificity, and lower detection limit of the RNAflow and RNAscope assays for the detection and description of the translation-competent HIV-1 reservoir. We also checked for HIV-1 subtype specificity of the RNAscope assay using patient-derived subtype A1, B, C, and CRF01_AE recombinant plasmids following transfection in 293T cells and the applicability of the method in patient-derived peripheral blood mononuclear cells (PBMCs). The lower detection limit of RNAflow was 575 HIV-1 infected cells/million and 45 cells/million for RNAscope. The RNAscope probes, designed for HIV-1B, also detected other subtypes (A1, B, C, and CRF01_AE). RNAscope was applicable for the detection of HIV-1 in patient-derived PBMCs following LRA activation. In conclusion, our study showed that RNAscope can be used to quantify the number of directly observed individual cells expressing HIV-1 mRNA following LRA activation. Therefore, it can be a useful tool for characterization of translation-competent HIV-1 in latently infected cell at single-cell resolution in the fields of HIV-1 pathogenesis and viral persistence.

Citing Articles

Natural killer cells induce HIV-1 latency reversal after treatment with pan-caspase inhibitors.

Furtado Milao J, Love L, Gourgi G, Derhaschnig L, Svensson J, Sonnerborg A Front Immunol. 2022; 13:1067767.

PMID: 36561752 PMC: 9763267. DOI: 10.3389/fimmu.2022.1067767.


Cancer as microenvironmental, systemic and environmental diseases: opportunity for transdisciplinary microbiomics science.

Inamura K, Hamada T, Bullman S, Ugai T, Yachida S, Ogino S Gut. 2022; .

PMID: 35820782 PMC: 9834441. DOI: 10.1136/gutjnl-2022-327209.


T cell stimulation remodels the latently HIV-1 infected cell population by differential activation of proviral chromatin.

Lindqvist B, Jutte B, Love L, Assi W, Roux J, Sonnerborg A PLoS Pathog. 2022; 18(6):e1010555.

PMID: 35666761 PMC: 9203004. DOI: 10.1371/journal.ppat.1010555.


Hybridization Chain Reaction for mRNA Localization in Single Cells from Mouse and Human Cryosections.

May-Zhang A, Benthal J, Southard-Smith E Curr Protoc. 2022; 2(5):e439.

PMID: 35612422 PMC: 9202517. DOI: 10.1002/cpz1.439.


Detection of Chimeric Cellular: HIV mRNAs Generated Through Aberrant Splicing in HIV-1 Latently Infected Resting CD4+ T Cells.

Lee M, Khoury G, Olshansky M, Sonza S, Carter G, McMahon J Front Cell Infect Microbiol. 2022; 12:855290.

PMID: 35573784 PMC: 9096486. DOI: 10.3389/fcimb.2022.855290.


References
1.
Rasmussen T, Lewin S . Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?. Curr Opin HIV AIDS. 2016; 11(4):394-401. DOI: 10.1097/COH.0000000000000279. View

2.
Laird G, Eisele E, Rabi S, Lai J, Chioma S, Blankson J . Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 2013; 9(5):e1003398. PMC: 3667757. DOI: 10.1371/journal.ppat.1003398. View

3.
Neogi U, Singh K, Aralaguppe S, Rogers L, Njenda D, Sarafianos S . Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. AIDS. 2017; 32(4):469-476. PMC: 5790636. DOI: 10.1097/QAD.0000000000001726. View

4.
Procopio F, Fromentin R, Kulpa D, Brehm J, Bebin A, Strain M . A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. EBioMedicine. 2015; 2(8):874-83. PMC: 4563128. DOI: 10.1016/j.ebiom.2015.06.019. View

5.
Joos B, Fischer M, Kuster H, Pillai S, Wong J, Boni J . HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A. 2008; 105(43):16725-30. PMC: 2575487. DOI: 10.1073/pnas.0804192105. View